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1. Introduction
  As the approaching of aging society, senile dementia is 
gradually turning into a serious medical issue that affects 
both medical sector and society. Vascular cognitive 
impairment (VCI) is a large class of syndrome from mild 
cognitive impairment to dementia caused by risk factors 
of cerebrovascular disease, obvious or not obvious 
cerebrovascular disease[1]. Vascular cognitive impairment 
of none dementia (VCIND), not reaching the dementia 
stage, can be controlled and reversed with medicine[2]. It is 
proposed by oversea scholars that vascular dementia (VD) 
shall be replaced by VCI[3,4] and three types of VCI were 
proposed as well: VCIND, VD and Alzheimer’s disease with 
vascular factors. The crypticity of VCI symptoms makes it a 
main reason for the high morbidity of VD. 
  Gingko leaf, dry leaf of Ginkogo biloba, with main 
composition being flavonoids and terpene, is effective in the 
treatment of ischemic cerebrovascular disease and VD[5,6]. 
  There are two major problems in the evaluation of 
cognitive function at present: 1) neuropsychological 
scale used for cognitive appraisal could not determine 
the normal line easily; 2) the identification that whether 
cognitive impairment was caused by vessel factors or not is 
difficult[3]. In addition, the heterogeneity is also a reason. 
In this experiment, the intervention effect of Gingko leaf 
on VCIND patients was evaluated through the Montreal 
cognitive assessment (MoCA) rating scale and transcranial 
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conventional treatment with anti-platelet aggregation. In this group, 75 mg aspirin was given 
three times a day for 3 months. While in combined treatment group, 19.2 mg GBT was given three 
times a day for 3 months together with conventional treatment (anti-platelet aggregation drugs). 
Montreal cognitive assessment (MoCA) and transcranial Doppler (TCD) were used to observe 
changes of cognitive ability and cerebral blood flow in VCIND patients before and after treatment 
in both groups. Then the clinical data were analyzed so as to compare the efficacy in two groups. 
Results: After 3 month-treatment in combined treatment group, the scores of executive ability, 
attention, abstract, delayed memory, orientation in the MoCA were significantly increased 
compared with those before treatment and those in control group after treatment. Besides, blood 
flow velocity of anterior cerebral artery increased significantly than that before treatment and that 
in control group after treatment. Conclusions: GBT tablet can improve the therapeutic efficacy 
as well improve cognitive ability and cerebral blood flow supply of patients with VCIND.
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doppler (TCD) from the aspects of neural psychology and 
cerebral blood flow. It provided practical foundation and 
experimental basis for therapy of VCIND using traditional 
Chinese medicine as an adjunctive.
2. Materials and methods
2.1. Diagnosis and criteria
  By referring to related literature and relevant criteria, 
a criteria was made as follows: 1) 60-75 years old; 2) 
cognitive disorder shown by revised mini mental state 
examination (MMSE); 3) Cognitive impairment shown by 
neuropsychological evaluations; 4) Memory relatively 
reserved or slightly impaired while cognitive function such 
as attention and executive ability impaired seriously; 5)
Difficulty in identifying whether the cognitive function 
impairment was caused by vascular factors; 6) Hanchinski 
inchemic score ＞7; 7) Cognitive function impairment 
fluctuated. 
2.2. Subject
  Eighty cerebral infarction patients treated in our hospital 
from March 2009 to May 2011, including 46 males and 34 
females were enrolled. They were 60-75 years old and the 
average age was 66.5依5.6, including 35 hypertension, 42 
diabetes mellitus, and 33 cases of hyperlipemia. They were 
divided into two groups randomly: Conventional treatment 
group (n=40) and combined treatment group (n=40). There 
were no significant differences between the two groups in 
gender, age, cognitive rating scale score or TCD detection (P
＞0.05). All subjects should be examined by MoCA and TCD.
2.3. Methods
  75 mg aspirin enteric-coated tablets (Shijiazhuang 
Pharmaceutical Goup Ou Yi Pharmaceutical Industry 
Limited Company) was given to conventional treatment 
group 3 times a day for 3 months, while 40 mg oral Ginkgo 
biloba tablet (Tanakan EGb761, Tianjinbofu- Yi pu sheng 
Pharmaceuticals Co., Ltd., The registered number of the 
imported drugs: X19990156) was given to combined treatment 
group 3 times a day for 3 months on the basis of conventional 
treatment with anti-platelet aggregation drug. 
2.4. Monitoring indexes
2.4.1. MoCA
  Seven of the 30 indexes in MoCA such as executive ability, 
name, memory, attention, language, abstract, deferred 
memories and orientation force were chosen as analysis 
indexes. According to the severity of symptoms, patients 
were graded as 3, 2, 1 or 0 (for absence of symptoms). 
The decrease of clinical score ≥2/3 will be considered 
significant improvement while it ≥1/3 will be considered 
as partial improvement and the treatment is considered 
ineffective if the score remains the same.  
2.4.2. TCD evaluation
  Before and after the treatment, TCD meter probe from 
Germany Doppler-Box (2 MHz electromagnetic pulse) was 
applied through the temporal window and pillow window to 
detect the middle cerebral artery (MCA), anterior cerebral 
artery (ACA), posterior cerebral artery (PCA), vertebral 
artery (VA) and basilar artery (BA). Online state can real-
time display peak systolic velocity, end-diastolic velocity, 
average flow velocity, PI index, RI index and S/D ratio of 
blood flow frequency spectrum in two directions. 
2.5. Statistical method
All the data were processed by using SPSS software (Version 
13.0) and results were expressed as Mean依standard deviation 
(氈依sd). t test was used to test measurement data and氈
2 
was used for enumeration data. P<0.05 means that the tested 
difference had statistical significance.
3. Result
3.1. Comparison of MoCA score indexes before and after 
treatment
  In conventional treatment group and combined treatment 
group, there were no obvious differences in the seven scores 
and the total score of MoCA before and after treatment (P
＞0.05). After treatment, the scores of five indexes (except 
naming and language) and the total score in combined 
treatment group were significantly different compared with 
those before treatment (P＜0.05, P＜0.01). Besides, the 
executive ability, attention, abstract, deferred memories, 
orientation force and the total score of MoCA in combined 
treatment group were also significantly different compared 
with  those of the control group after treatment (P＜0.05, 
Table 1).
3.2. Changes of blood flow monitored by TCD before and 
after treatment 
  There was no significant difference between conventional 
treatment group and combined treatment group in vascular 
velocity before treatment (P＞0.05),  blood flow velocity 
of MCA and ACA in combined treatment group increased 
remarkably after treatment, and there was significant 
difference compared with that before treatment (P＜0.05) as 
well as compared with the control group (P <0.05) ( Table 2).
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4. Discussion
  VCI is a large class of syndrome from mild cognitive 
impairment to dementia caused by disease risk factors 
of cerebrovascular disease, obvious or not obvious 
cerebrovascular diseases[7-9]. VCIND is the earliest clinical 
stage of VCI and is also likely to be the most common VCI 
type. VCIND is insidious and its cognitive impairment 
degree does not reach dementia diagnosis standard[10]. 
  Neuropsychological testing is not only an important tool 
for VCIND diagnosis but also an important method for 
curative judgment and defection of curative vest. There is 
no internationally recognized VCIND neuropsychological 
testing method at present. MoCA is the firstly recommended 
VCI neuropsychology screening scale with international 
specialists’ consensus[3,11-14]. MoCA has become an 
internationally used screening scale that was verified by 
many evidence-based medicine for screening MCA and 
VCI. This screening scale is improved and established 
from Nasreddine on the basis of cognitive item setting and 
scoring criteria in MMSE. MoCA emphasized more on the 
evaluation of executive function and attention. MoCA is the 
most important clinical checking tool for cognitive function, 
which has good sensitivity compared with MMSE. But its 
results will be influenced by gender, age and educational 
level. There were no statistical differences in gender, age 
and educational level of the patients in this research, which 
make the result avoid being affected by the above factors 
effectively. 
  Abnormal cerebral blood flow is a significant reason for the 
incidence of VCIND. TCD is a non-invasive cerebrovascular 
detection means, which directly reflects haemodynamic 
changes of intracranial vascular through determining blood 
flow velocity and vascular resistance index[15-17]. TCD 
is mainly used to detect blood flow states and vascular 
function. It is reported that[18] the incidence of abnormal 
hemodynamics studied with TCD in VCI patients was higher 
than those of control group and cerebral stoke group. There 
was a positive correlation between MoCA score and TCD 
results in this group, indicating that MoCA and TCD can be 
jointly used for evaluating mild VCI. The outpatient visit rate 
and diagnostic rate among people with cognitive disorder 
and dementia in China is relative low. Survey shows that the 
outpatient visit rate among dementia population is around 
23.3%, which is less than half of that in developed country. 
By using neuropsychological tests, even slight degree of 
cognitive disorder can be detected, which enables patients 
to receive early treatment so as to prevent and postpone the 
occurrence and development of dementia symptoms. 
  Flavonoids are main and effective components of Ginkgo 
biloba leaf. Pharmacological study shows that aqueous 
extracts of Ginkgo biloba leaf have pharmacological effects 
such as antioxidant activity and antiradical activity. It 
can reduce myocardial oxygen consumption, protect for 
injuries from reperfusion for myocardial ischemia, protect 
smooth muscle cell of cerebral microvessels, improve neural 
plasticity and neurodegenerative disease[6,19-21], and can 
Table 1 
Scores of all indexes of MoCA before and after treatment. 
Index
Conventional treatment group Combined treatment group
Before treatment After treatment Before treatment After treatment
Executive ability   2.25依1.21            1.97依1.22               2.49依0.77              4.02依0.49△*
Name   0.97依0.56            0.98依0.45               1.15依0.93          1.40依0.56
Attention   2.14依1.05           2.29依0.73               2.31依0.41                 4.61依0.42△△*
Language   1.51依0.33           2.02依0.31               1.42依0.45          2.22依0.38
Abstract   0.82依0.70            0.86依0.52               0.78依0.59              1.67依0.35△*
Deferred memories   1.01依0.84            0.89依0.71               1.11依0.56              3.03依0.37△*
Orientation force   4.02依0.46            3.95依0.89               3.43依0.39              5.34依0.91△*
Total score 11.46依2.98         12.99依2.81             12.42依2.66            19.10依2.94△*
Note: *P<0.05, compared with that before treatment; △△P<0.01, △P<0.05,compared  with control group. 
Table 2  
Result of TCD spectrum blood flow velocity (Vm) before and after treatment (cm/s).
Index
Conventional treatment group Combined treatment group
Before treatment After treatment Before treatment After treatment
MCA  52.1依9.7                  56.2依8.9                          51.5依9.4                          79.6依11.2△*
ACA    43.5依12.2                   48.3依11.1                         47.6依12.8                      72.1依10.3△*  
PCA 37.6依5.9               42.3依7.5                          40.2依6.4                  49.8依9.1  
VA   42.8依10.1                 45.7依10.2                          42.1依8.2                      52.3依10.1
BA 40.9依5.8                 31.1依7.7                         42.7依8.8                    49.9依6.5
Note: *P＜0.05, compared with that before treatment; △P＜0.05, compared with the control group.
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be used in early intervening treatment of VCIND patients. 
This research observed the clinical intervention effects of 
joint treatment of GBT and anti-platelet aggregation drug on 
VCIND patients. It shows that the score of patients’ executive 
ability, attention, deferred memory, abstract, orientation 
force all increased significantly after 3 month-treatment, 
which indicated that GBT can improve the cognitive function 
of VCIND patients. And the blood flow velocity of MCA, 
ACA increased obviously after taking GBT, indicating that 
the regional cerebral blood flow in the area where frontal 
lobe and temporal lobe have a close relation with cognitive 
function increased significantly. This experiment verified 
that GBT can improve the cognitive ability of VCIND and the 
supply of their cerebral blood flow.
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